Gavreto Archives -

Eli Lilly’s RET inhibitor Retsevmo can now be prescribed on the NHS for people with RET fusion-positive advanced

After Scotland says no, NICE backs Lilly’s Retsevmo for lung cancer

https://pharmaphorum.com/news/after-scotland-says-no-nice-backs-lillys-retsevmo-for-lung-cancer/

Roche and Blueprint Medicines have opened a second front in their rivalry with Eli Lilly in RET-mutated cancers,

Roche, Blueprint’s RET cancer drug Gavreto cleared in EU

https://pharmaphorum.com/news/roche-blueprints-ret-cancer-drug-gavreto-cleared-in-eu/

The FDA has cleared Roche and Blueprint Medicine’s Gavreto for a new use in RET-mutated thyroid cancer, putting

Roche, Blueprint raise pressure on Lilly with new Gavreto approval

https://pharmaphorum.com/news/roche-blueprint-raise-pressure-on-lilly-with-new-gavreto-approval/

Gavreto